%0 Journal Article
%A Olivares-Hernandez, Alejandro
%A Del-Barco-Morillo, Edel
%A Miramontes-Gonzalez, Jose Pablo
%A Figuero-Perez, Luis
%A Perez-Belmonte, Luis
%A Martin-Vallejo, Javier
%A Martin-Gomez, Teresa
%A Escala-Cornejo, Roberto
%A Vidal-Tocino, Rosario
%A Bellido-Hernandez, Lorena
%A Gonzalez-Sarmiento, Rogelio 
%A Ludeña-de-la-Cruz, Maria Dolores
%A Cruz-Hernandez, Juan Jesus
%A Parra-Perez, Carmen 
%T Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy.
%D 2022
%U http://hdl.handle.net/10668/21810
%X Determining predictive biomarkers for immune checkpoint inhibitors (ICIs) is a current challenge in oncology. Previous studies on non-small cell lung cancer (NSCLC) have shown how TP53 gene mutations are correlated with different responses to ICIs. Strong and diffuse immuno-expression of p53 by immunohistochemistry (IHC) is interpreted as a likely indicator of a TP53 gene mutation. We aimed to assess the p53 protein expression via IHC in NSCLC as a predictive biomarker of the response to ICIs. This was a retrospective hospital-based study of patients with NSCLC treated with Nivolumab in the University Hospital of Salamanca. All diagnostic biopsies were studied via IHC (measuring p53 protein expression, peroxidase anti-peroxidase immunohistochemistry technique using Leica BOND Polymer development kits). Survival analysis was performed by subgroups of expression of p53 and other factors using the Kaplan-Meier estimator and Cox proportional-hazards model. Seventy-three patients were included (59 men and 14 women). The median age was 68 (44-84) years. Thirty-six biopsies were adenocarcinoma, 34 were squamous, and three were undifferentiated. In 41 biopsies (56.2%), the cellular expression of p53 was  A trend toward a greater response to ICIs was observed in the PFS and OS of patients with high expression of p53 by IHC (TP53 mutation), especially in the PD-L1 negative adenocarcinoma subgroup. These results will make it possible to make future modifications to the clinical guidelines of NSCLC according to the expression of p53.
%K Biomarkers
%K Immune checkpoint inhibitors
%K Immunotherapy
%K Non-small cell lung cancer
%K p53 protein
%~